Latanoprost ophthalmic solution - TearClear
Alternative Names: TC-002Latest Information Update: 04 Oct 2022
At a glance
- Originator TearClear
- Class Antiglaucomas; Eye disorder therapies; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Glaucoma
Most Recent Events
- 29 Sep 2022 TearClear plans to file a new drug application (NDA) with the US Food and Drug Administration (FDA) for Glaucoma in the first quarter of 2023
- 29 Sep 2022 Efficacy data from a phase III trial in Glaucoma released by TearClear
- 29 Nov 2021 Phase-III clinical trials in Glaucoma in USA (Ophthalmic) (NCT05165290)